Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
1,294 total articles
Freeport-McMoRan Executive Vice President and Chief Financial Officer Maree E. Robertson sold 48,500 shares of common stock on February 13, 2026, for roughly $2.9 million, and separately sold 10,354 shares on February 15, 2026, to cover taxes from vested restricted stock units. The company has also formalized a Memorandum of Understanding with Indo…
Matthew E. Forstenhausler, a director at Sound Point Meridian Capital, Inc. (NASDAQ: SPMC), bought 2,000 shares on February 13, 2026, according to a Form 4 filing. The purchase totaled $23,000 at $11.50 per share—roughly 9% above the stock's reported trading price of $10.53 and about 1% above its 52-week low of $10.41. After the transaction, Forste…
Microsoft director John W. Stanton bought 5,000 shares of Microsoft common stock at $397.35 per share, totaling $1.98 million. After the purchase on February 18, 2026, Stanton’s direct holdings rose to 83,905 shares, with an additional 3,622 shares held indirectly through a family trust. The transaction coincides with several AI industry updates, i…
Peloton Interactive's Chief Accounting Officer, Saqib Baig, sold 36,640 shares of Class A common stock for roughly $152,586 following an earlier exercise of Restricted Stock Units. The insider transactions came amid Peloton's fiscal second-quarter 2026 results that missed revenue expectations and prompted a range of analyst reactions.
Globe Life Co-Chairman and CEO Frank M. Svoboda sold 12,500 shares of common stock on February 17, 2026, generating $1,809,702 in proceeds and exercised options to acquire an additional 12,500 shares at $82.56 per share for $1,032,000. The company also reported fourth-quarter 2025 results that missed analyst expectations on both earnings per share …
Exelixis director Sue Gail Eckhardt sold 3,856 shares of the company's common stock on February 13, 2026, for roughly $168,854. The transaction occurred under a pre-established Rule 10b5-1 plan. The company reported a fourth-quarter 2025 EPS beat even as revenue fell slightly short of expectations, and analysts and management actions point to conti…
Julie Green, Invivyd Inc.'s Chief Human Resources Officer, sold 40,627 shares of the company's common stock across two trades on February 17-18, 2026, for roughly $63,350. The sales followed the vesting of restricted stock units and were intended to satisfy tax obligations after Green exercised options on 99,000 shares on February 15. Invivyd is re…
Invivyd, Inc. (NASDAQ: IVVD) reported that Chief Scientific Officer Robert D. Allen III sold common stock totaling roughly $58,600 across two transactions on February 17 and 18, 2026. The sales - executed under a pre-arranged Rule 10b5-1 trading plan to satisfy tax liabilities triggered by RSU vesting - follow an option exercise earlier in the mont…
Genco Shipping & Trading LTD's Chief Financial Officer, Peter George Allen, executed a sale of 6,232 shares on February 18, 2026, while simultaneously receiving newly settled restricted stock units. The company is also advancing a fleet acquisition and evaluating a non-binding cash proposal from Diana Shipping Inc., which holds roughly 14.8% of Gen…
Genco Shipping & Trading Ltd.'s Chief Commercial Officer Jesper Christensen executed share sales worth about $192,210 on February 18, 2026, while also receiving performance-based stock in settlement of vested restricted units. The company is simultaneously moving forward with a two-vessel acquisition and reviewing an unsolicited proposal from Diana…
Genco Shipping & Trading Ltd's (NYSE:GNK) Chairman, CEO and President John C. Wobensmith sold 18,642 shares on February 18, 2026, for roughly $433,612 while acquiring performance-based restricted stock units the same day. The company has also agreed to buy two 2020-built Newcastlemax vessels for $145.5 million and is evaluating a non-binding all-ca…
Solid Biosciences Chief Regulatory Officer Jessie Hanrahan sold 4,134 shares of common stock on February 18, 2026, for $24,073 to meet withholding tax obligations tied to vested restricted stock units. Earlier that month Hanrahan received 8,125 shares and 8,125 restricted stock units. Separately, Solid says it has secured FDA agreement on the Phase…
Solid Biosciences Inc. Chief Financial Officer Kevin Tan sold 5,404 shares on February 18, 2026 to meet withholding tax obligations tied to vested restricted stock units, while earlier exercising options to acquire 10,625 shares. The company is progressing multiple clinical programs and has received an Orphan Drug designation, even as its market ca…
A director of Solid Biosciences saw his wife sell 2,658 shares of the company's common stock on February 18, 2026, at a weighted average price of $5.8233, raising $15,478 to satisfy withholding tax obligations tied to vested restricted stock units. The action follows a February 13 conversion of 4,861 RSUs into shares and comes as the company moves …
Solid Biosciences Chief Operating Officer David T. Howton sold 7,469 shares on February 18, 2026, to cover withholding taxes after restricted stock units vested. The transactions were executed across prices of $5.23 to $6.14, totaling roughly $43,494. The company continues advancing clinical programs, including FDA agreement on a Phase 3 study desi…
Patrick Industries (NASDAQ: PATK) reported an insider sale by Chief Legal Officer and Secretary Joel D. Duthie who sold 2,660 shares on February 17, 2026, for $141.03 per share, totaling $375,139. The transaction leaves Duthie with 33,018 shares. The move comes after a strong fourth quarter of 2025 that beat analyst forecasts for both earnings and …
Paul Herzich, Chief Technology Officer of Solid Biosciences Inc. (NASDAQ:SLDB), sold 3,616 shares on February 18, 2026 for roughly $21,057 to cover withholding taxes after restricted stock units vested. Herzich had exercised RSUs and acquired 7,187 shares on February 13, 2026. The company has secured FDA agreement on the design of its Phase 3 IMPAC…
Solid Biosciences President and CEO Alexander Cumbo disposed of 16,644 common shares on February 18, 2026, to satisfy withholding tax obligations tied to vested restricted stock units. The sale, executed at a weighted average price of $5.8233 per share, totaled approximately $96,923. The company is approaching an earnings report on March 6 and has …
Johnson & Johnson Executive Vice President and Chief Financial Officer Joseph J. Wolk disposed of 84,654 shares on February 17, 2026, generating roughly $21.7 million. The Form 4 filing shows additional option exercises and share conversions, tax-related dispositions, and a post-transaction ownership breakdown. The transactions come amid the compan…
Joseph Adamo, Chief Accounting Officer at Genco Shipping & Trading Limited, sold 3,227 shares on February 18, 2026 for roughly $75,092 while receiving 7,170 shares from vested performance restricted stock units. Separately, Genco agreed to acquire two Newcastlemax vessels for $145.5 million and has received a non-binding cash offer from Diana Shipp…
Johnson & Johnson Executive Vice President and Chief Investment Officer James D. Swanson completed a series of equity transactions in mid-February 2026 that included the sale of common shares, the exercise of employee stock options and the conversion of restricted and performance share units. Those moves occurred alongside the company’s announcemen…
Booking Holdings Inc. NASDAQ:BKNG CEO and President Glenn D. Fogel sold $2.25 million in common stock in two transactions recorded on a Form 4 with the SEC. The trades took place on February 10 and February 17, 2026, as the shares were trading close to a 52-week low and down more than 20% year-to-date. The company reported stronger-than-expected fo…
Exelixis director Oliver Bob sold 30,250 shares on February 13, 2026, in two trades totaling about $1.3 million and concurrently exercised options to acquire 9,088 shares. The transactions, recorded on a Form 4 filing, leave Bob with direct ownership of 21,120 Exelixis shares. Separately, Exelixis reported Q4 2025 results that beat EPS estimates bu…
Exelixis Senior Vice President and General Counsel Brenda Hefti sold 18,669 shares on February 18, 2026, raising about $821,622 through transactions executed under a Rule 10b5-1 plan. Additional shares were sold on February 15 to cover tax obligations tied to vesting performance-based RSUs. The insider activity coincides with an EPS beat for Q4 202…
Invivyd Inc.'s Chief Financial Officer, William E. Duke, executed sales totaling 40,627 common shares on February 17 and 18, 2026, for approximately $63,350. The transactions followed option exercises and RSU conversions on February 15, and come as the company receives FDA feedback on its planned Phase 3 LIBERTY study of VYD2311. H.C. Wainwright ha…
